相关临床试验
4
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
招募中
3
75.0%
终止
1
25.0%
暂无批准数据
- The Second International Conference on Innovations in Pharma R&D (InnoPharm 2026) will take place November 2–4, 2026, at the Holiday Inn Boston Hotel in a hybrid format. - Plenary and keynote speakers include researchers from Harvard, Stanford, Yale, UC San Diego, NIH, and other leading institutions, covering drug discovery, AI, precision medicine, and drug delivery. - A dedicated Drug Discovery & Optimization track, chaired by Girish Nallur of Vistara Bioscience, will feature experts from HitGen, DeepCovalent, Mayo Clinic, and Boston University. - The conference aims to foster global collaboration across academia, industry, healthcare, and regulatory science to accelerate translation of research into healthcare solutions.
- Mission BioCapital launches its 2026 Platinum Program offering up to $500,000 in pre-seed funding to eight biotech startups globally, with applications open from April 1 to May 15, 2026. - The program has deployed $11.5 million across 24 companies since 2022, with new sponsors AbbVie, TIAP, Connecticut Innovations, CCRM, and Norton Rose Fulbright joining existing partners. - Eight 2025 winners were announced, developing innovative therapies ranging from pregnancy-safe monoclonal antibodies to precision immunotherapies and targeted protein degradation platforms. - Winners receive comprehensive support including guaranteed lab space across 31 incubators in 22 cities, drug discovery services, and strategic mentorship from industry experts.
- HitGen Inc. has entered into a new contract agreement with the Gates Foundation to leverage its DNA-encoded library platform for discovering novel therapeutics targeting underserved diseases. - The company will conduct screening against 15 drug targets for tuberculosis, malaria treatment, and non-hormonal contraception agents using its platform of over 1.2 trillion small molecules. - This funding builds upon a previous Gates Foundation-supported project where HitGen successfully identified novel drug leads for malaria and tuberculosis treatment. - The collaboration represents HitGen's continued commitment to addressing unmet medical needs in global health through its world-leading DEL technology platform.
